A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.
About this trial
This trial is enrolling 10 participants with traumatic spinal cord injury to test the safety of a drug (andecaliximab) designed to prevent abnormal bone growth in soft tissues such as muscles and tendons. If included, participants will receive weekly subcutaneous injections of andecaliximab for 8 weeks. Final testing of safety will be performed after 13 weeks.
Included participants
Traumatic
What’s involved
Type
Details
- Participants will receive 8 weekly subcutaneous injections of andecaliximab. - Andecaliximab is a drug designed to prevent abnormal bone growth in soft tissues like muscles and tendons, which can occur after a spinal cord injury. - Final testing of safety will be performed after 13 weeks.
Potential benefits
Main benefits
General health
Additional benefits
Bone health
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more- Trial recruitment status
- Recruiting
- Trial start date
- 14 May 2025
- Organisation
- Ashibio Inc
- Trial recruitment status
- Recruiting
- Trial start date
- 14 May 2025
- Organisation
- Ashibio Inc
About this trial
Included participants
What’s involved
Potential benefits
Wings for Life supports SCITrialsFinder
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more